Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.67 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.62 |
| ▸ | BRD4 | O60885 | 3/20 | 0.62 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.62 |
| ▸ | TNF | P01375 | 1/20 | 0.62 |
| ▸ | IL1B | P01584 | 1/20 | 0.62 |
| ▸ | MAP1LC3B | Q9GZQ8 | 5/20 | 0.61 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17536564 | 0.94 | CRBN (0.64) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL30042744 | 0.92 | CRBN (0.62) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL28909798 | 0.92 | CRBN (0.62) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL17536570 | 0.91 | CRBN (0.66) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL24818144 | 0.90 | CRBN (0.65) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL29822441 | 0.90 | CRBN (0.65) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL17536589 | 0.90 | STAT3 (0.65) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL31601583 | 0.89 | CRBN (0.64) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL21602681 | 0.89 | CRBN (0.64) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL21907827 | 0.89 | CRBN (0.64) | CRBNIKZF3BRD4IKZF1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| CN-116323580-A | Conjugated degradation (EGFR) of EGFR inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022012622-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | CRBN 144/4885IKZF3 999/4885BRD4 2124/4885 |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | CRBN 1/4885IKZF3 248/4885BRD4 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.